702, 7th Floor, Solaris Kode, Near Khatu Shyam Temple, VIP Road, Vesu , Surat.
drjennygandhi98@gmail.com
+91 90033 03373
1. Preparing for the Procedure
Patient fasting for 4-6 hours prior. Vital sign monitoring, peripheral intravenous access, and informed consent were established.
Trabsarterial Chemo embolization
Trabsarterial Chemo embolization
procedure steps
2. Access to Vascular
The Seldinger procedure is used to get arterial access under local anesthesia, typically through the femoral artery (groin) or radial artery (wrist). Over a guidewire, a vascular sheath is placed into the artery.
3. Navigation of Catheters
Under fluoroscopic (X-ray) guidance, a diagnostic catheter is inserted into the hepatic artery supplying the tumor, the celiac trunk, and the abdominal aorta. The tumor-feeding arterial branch is reached by superselective catheterization using a microcatheter.
4. Delivery of Chemoembolization
An embolic agent, such as lipiodol or drug-eluting beads, is combined with a chemotherapeutic medication (often doxorubicin or cisplatin) and injected directly into the artery supplying the tumor. Embolic particles obstruct blood flow, trapping chemotherapy inside the tumor and depriving it of oxygen and nourishment.
5. Verification of Imaging
To ensure sufficient embolization and blocking of the tumor's blood supply, fluoroscopy is employed both during and after the treatment.
6. Removal of the Sheath and Catheter
Carefully remove the sheath and catheter. Hemostasis is achieved by manually compressing the artery puncture site or using a closure device.
7. Monitoring Following the Procedure
For a few hours or overnight, the patient is monitored in a recovery facility. Vital signs are tracked, as are any consequences (such as bleeding, discomfort, or infection).
disease treated
Liver Cancer
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Renal Tumors
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Pain From Metastatic Lesions
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
suitable for
Patients with Intermediate-Stage Hepatocellular Carcinoma
Individuals with unresectable tumors without significant vascular invasion or extrahepatic metastasis who have intermediate-stage hepatocellular carcinoma (HCC), particularly those categorized as Barcelona Clinic Liver Cancer (BCLC) stage B.
Individuals Unfit for Ablation or Surgery
those whose tumors, because of their size, location, or comorbidities, cannot be surgically removed or efficiently treated with ablation therapy.
Hepatic Artery-Driven Liver Tumors
Patients must have intact portal vein flow because TACE targets the hepatic artery’s blood supply.
Individuals Waiting for a Liver Transplant
used as a bridging medication to prevent tumor development and maintain transplant eligibility.
Individuals with Other Cancer Metastases to the Liver
When systemic therapy is inadequate, it can be utilized for metastatic tumors in the liver from colorectal, breast, neuroendocrine, and other malignancies.
Sufficient Liver Performance and Function
To tolerate the surgery, candidates typically need to have a good overall health state (ECOG 0-1) and a good liver reserve (Child-Pugh Class A or early B).
Unsuitable
Patients with significant liver dysfunction, a large tumor burden that affects more than 50% of the liver volume and cannot be treated in stages, portal vein thrombosis without collaterals, or extrahepatic dissemination should not use this medication.
benefits
Enhanced Survival
With a 1-year survival rate of roughly 75–80% and a 2-year survival rate of roughly 55–57% in certain individuals, TACE dramatically increases the survival rates of patients with incurable hepatocellular carcinoma (HCC).
Tumor Management
By administering chemotherapy directly to the tumor’s blood supply and obstructing arterial flow, it causes tumor necrosis and shrinking, providing targeted and efficient tumor control.
Reduced Systemic Toxicity
Compared to systemic chemotherapy, targeted administration reduces side effects by limiting systemic exposure to chemotherapy.
Bridging and Palliative Therapy
As a bridging therapy to liver transplantation, it stops tumor growth while patients wait for a transplant and relieves symptoms while controlling tumor progression in palliative situations.
Compatibility of Combination Therapy
demonstrates synergistic effects when paired with other medicines, such as molecular therapies or radiofrequency ablation (RFA), increasing the total efficacy of treatment.
Maintains Healthy Liver Tissue
Because the liver has two blood supplies, the portal vein and the hepatic artery, embolizing the arteries supplying the tumor reduces damage to healthy liver tissue.
Repeatable and Outpatient Procedure
TACE is frequently done as an outpatient procedure and can be repeated several times to treat new lesions or maintain tumor control.
Improved Life Quality
TACE enhances the quality of life for patients with advanced liver cancers by managing tumor development and symptoms.
post-treatment recovery
Hospitalization and Early Recuperation
Following a procedure, patients typically remain in the hospital for one to two days in order to monitor and treat symptoms including pain and nausea.
Common Adverse Reactions
Fever, exhaustion, nausea, vomiting, stomach pain, and appetite loss are some of the symptoms.
Although they can last up to two weeks or more, these effects usually last five to seven days.
Management of Pain and Symptoms
Oral or intravenous drugs are used to treat pain and nausea both during and after hospital stays.
Usually, fever is mild and fleeting.
Limitations on Activities
It is recommended that patients refrain from physically demanding activities and relax for a few days.
While some fatigue may last longer, most people may resume their regular daily activities in approximately a week.
Monitoring and Follow-Up
Four to six weeks after TACE, blood tests and follow-up imaging (CT or MRI) are usually performed to assess therapeutic response.
Depending on how the tumor responds, additional therapies may be planned.
Possible Difficulties
Bile duct damage, sepsis, and liver failure are uncommon but dangerous side effects.
Increasing abdominal pain, a high fever, jaundice, or confusion are examples of worsening symptoms that patients must report right once.
Long-Term Prospects
Many patients recover well and have better tumor control and quality of life when they receive the right care.
